We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
62.00 | 0.50% | 12,394.00 | 12,392.00 | 12,396.00 | 12,432.00 | 12,314.00 | 12,350.00 | 627,432 | 14:23:45 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 32.31 | 192.41B |
By Chris Wack
AstraZeneca and Daiichi Sankyo Co. said they said the saw positive results from a Phase II trial that showed Enhertu provided a clinically meaningful and durable tumor response in patients with HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma previously treated with a trastuzumab-containing regimen.
Enhertu fam-trastuzumab deruxtecan-nxki is an HER2-directed antibody drug conjugate intended to treat gastric cancer.
In the primary analysis, the first trial of Enhertu specifically in Western patients with HER2-positive metastatic gastric cancer or GEJ adenocarcinoma, Enhertu demonstrated a confirmed overall response rate of 38% as assessed by independent central review.
Three complete responses and 27 partial responses were observed in patients treated with Enhertu. These results were consistent with those from a previous registrational Phase II trial.
After a median follow-up of 5.7 months, the median duration of response of Enhertu was 8.1 months. The median progression-free survival was 5.5 months. An exploratory endpoint of confirmed disease control rate of 81% was seen.
Enhertu is approved in Israel, Japan and the U.S. for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 17, 2021 12:50 ET (16:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions